国际麻醉学与复苏杂志   2023, Issue (2): 5-5
    
复合丙泊酚时阿芬太尼抑制结肠镜检查患者体动反应的半数有效量
柳胜安, 郭姚邑, 侯丕红, 杜佳月, 李浩甲, 鲍红光, 史宏伟, 斯妍娜1()
1.江苏省中西医结合医院
The median effective dose of alfentanil for inhibiting motor responses in patients undergoing colonoscopy when combined with propofol
 全文:
摘要:

目的 探讨复合丙泊酚时阿芬太尼抑制结肠镜检查患者体动反应的半数有效量(median effective dose, ED50)。 方法 择期行无痛结肠镜检查的患者25例,性别不限,年龄18~65岁,BMI 18~25 kg/m2,ASA分级Ⅰ、Ⅱ级。患者静脉推注阿芬太尼,初始剂量5 μg/kg,随后以2.0 mg·kg−1·min−1速率静脉泵注丙泊酚,待BIS为65时行结肠镜检查。依据Dixon序贯法确定下1例患者阿芬太尼剂量。记录患者阿芬太尼剂量,入室平静呼吸时(T0)、给药后BIS值65时(T1)、结肠镜通过降结肠乙状结肠移行段时(T2)、达回盲瓣后退镜时(T3)、睁眼时(T4)的MAP、心率、SpO2及不良反应发生情况。采用概率单位回归分析方法计算阿芬太尼抑制结肠镜检查体动反应的ED50、95%有效量(95% effective dose, ED95)及其95%CI。 结果 与T0比较,患者T1~T4时MAP下降(P<0.05),T1~T3时心率下降(P<0.05),T2时SpO2下降(P<0.05)。2例(8%)患者自诉轻微注射痛,1例(4%)患者发生心动过缓,6例(24%)患者发生低血压,所有患者未出现肌肉僵直、腹痛、术后恶心呕吐。复合丙泊酚时阿芬太尼抑制结肠镜检查体动反应的ED50、ED95及其95%CI分别为4.968(4.488~5.376) μg/kg、5.784(95.376~8.698) μg/kg。 结论 复合丙泊酚时阿芬太尼抑制结肠镜检查患者体动反应的ED50为4.968 μg/kg,ED95为5.784 μg/kg。

关键词: 阿芬太尼; 丙泊酚; 结肠镜检查; 半数有效量
Abstract:

Objective To determine the median effective dose (ED50) of alfentanil for inhibiting motor responses in patients undergoing colonoscopy when combined with propofol. Methods Twenty‑five patients, men or women, aged 18‒65 years, body mass index (BMI) 18‒25 kg/m2, American Society of Anesthesiologists (ASA) physical status Ⅰ or Ⅱ, who underwent elective painless colonoscopy were selected. The patients were intravenously infused with alfentanil, with an initial dose of 5 μg/kg, before intravenous administration of propofol at a dose of 2.0 mg·kg−1·min−1. Colonoscopy was performed when the bispectral index (BIS) was 65. The dose of alfentanil in the next patient was determined according to Dixon's up‑and‑down method. The dose of alfentanil was recorded. Their mean artery pressure (MAP), heart rate, pulse oxygen saturation (SpO2), and adverse reactions were recorded when the patients breathing calmly in the room (T0), when the BIS value was 65 after administration (T1), when the colonoscope passed through sigmoid-descending colon junction (T2), when the colonoscope was withdrawn after arriving at the ileocecal valve (T3), and when the patient's eyes were open (T4). The ED50, 95% effective dose (ED95) and 95% confidence interval (CI) of alfentanil for inhibiting motor responses undergoing colonoscopy were calculated by probit regression. Results Compared with those at T0, MAP decreased at T1‒T4 (P<0.05), heart rate decreased at T1‒T3 (P<0.05), and SpO2 decreased at T2 (P<0.05). Two (8%) patients complained of mild injection pain, 1 (4%) patient developed bradycardia, 6 (24%) patients developed hypotension, and none of the patients had muscle stiffness, abdominal pain, or postoperative nausea and vomiting. The ED50 and 95%CI of alfentanil when combined with propofol for inhibiting motor responses in patients undergoing colonoscopy was 4.968 (4.488‒5.376) μg/kg, while the ED95 and 95%CI was 5.784 (5.376‒8.698) μg/kg. Conclusion The ED50 and ED95 of alfentanil combined with propofol for inhibiting motor responses in patients undergoing colonoscopy was 4.968 and 5.784 μg/kg respectively.

Key words: Alfentanil; Propofol; Colonoscopy; Median effective dose